[CLSTR]
< Back to situations

[ORGANIZATION]

Sanofi

Featured in 6 tracked stories · first seen

Situations

[ACTIVE] [BUSINESS] [HEALTH] [DE] [FR]

Sanofi halts Amlitelimab development

2 clusters · 11 sources · last updated

Latest: Sanofi Halts Development of Amlitelimab for Atopic Dermatitis

In late July 2026, Sanofi announced it would stop pursuing its experimental antibody Amlitelimab for atopic dermatitis. The company cited insufficient efficacy and safety data from the Phase 3 COAST‑1 trial, including is

Also covered in